Specialty and rare disease DTC audiences
Blueprint builds DTC audiences for specialty and rare disease brands where precision matters and prevalence is low.
How it works
Blueprint's cohort-verified method replaces prediction with proof, guessing with actual knowledge.
Select Groups
Random pseudonymous groups, no identifiers or PII.
Validate Accuracy
Measure condition prevalence using de-identified claims. We only learn about the group, never about an individual.
Assemble Cohorts
Combine verified groups for the right balance of size and precision.
Distribute
Deliver ready-to-activate audiences to your preferred ad platforms.
Real patients. Zero inferences. Privacy built in.
When to use Blueprint
Blueprint performs best when traditional DTC audiences struggle.
Rare disease and specialty brands
Oncology, immunology, and neurology
Low awareness or early-market therapies
Campaigns where missing patients is costly
How Blueprint DTC audiences are different
Most DTC health audiences rely on consumer behavior data and predictive models.
In specialty and rare disease, those approaches often miss real patients.
Legacy Vendors
Built on predictive models or lookalikes
Relies on consumer behavior data
Struggles with low-prevalence populations
Blueprint Audiences
Built without predictive models or lookalikes
No consumer behavior data
Designed for low-prevalence populations
More accuracy. Less risk. Better results.
Activate anywhere
Blueprint audiences can be distributed across every major ad platform.
Plus many more. Wherever you buy media, Blueprint audiences are ready to activate.
Get started
Start with a single specialty or rare disease audience and measure performance before scaling.